Cellular and molecular mechanisms of statins: An update on pleiotropic effects

Clinical Science

Volumn 129, Issue 2, 2015, Pages 93-105

  Satoh, Mamoru ^a   Takahashi, Yuji ^a   Tabuchi, Tsuyoshi ^a   Minami, Yoshitaka ^a   Tamada, Makiko ^a   Takahashi, Kan ^a   Itoh, Tomonori ^a   Morino, Yoshihiro ^a   Nakamura, Motoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Endothelial progenitor cells; MiRNA; SIRT 1; Telomere; Toll like receptor 4

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICRORNA 221; MICRORNA 222; MICRORNA 34A; SIRTUIN 1; TOLL LIKE RECEPTOR 4; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; LIPID; MICRORNA;

CARDIOVASCULAR RISK; CELL AGING; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TELOMERE; ANIMAL; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DRUG EFFECTS; DYSLIPIDEMIAS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DYSLIPIDEMIAS; ENDOTHELIAL PROGENITOR CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; LIPIDS; MICRORNAS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; TELOMERE; TREATMENT OUTCOME;

EID: 84935445023     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20150027     Document Type: Review

References (100)

1. Libby, P. (2002) Inflammation in atherosclerosis. Nature 420, 868-874.
2. Weber, C. and Soehnlein, O. (2011) ApoE controls the interface linking lipids and inflammation in atherosclerosis. J. Clin. Invest. 121, 3825-3827.
3. Ascer, E., Bertolami, M.C., Venturinelli, M.L., Buccheri, V., Souza, J., Nicolau, J.C., Ramires, J.A. and Serrano, Jr, C.V. (2004) Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177, 161-166.
4. van de Ree, M.A., Huisman, M.V., Princen, H.M., Meinders, A.E. and Kluft, C., DALI study group (2003) Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166, 129-135.
5. Järvisalo, M.J., Toikka, J.O., Vasankari, T., Mikkola, J., Viikari, J.S., Hartiala, J.J. and Raitakari, O.T. (1999) HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 147, 237-242.
6. Dupuis, J., Tardif, J.C., Cernacek, P. and Théroux, P. (1999) Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99, 3227-3233.
7. Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D., Zeiher, A., Chaitman, B.R., Leslie, S. and Stern, T., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study investigators (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285, 1711-1718.
8. Amarenco, P., Goldstein, L.B., Szarek, M., Sillesen, H., Rudolph, A.E., Callahan, 3rd, A., Hennerici, M., Simunovic, L., Zivin, J.A. and Welch, K.M., SPARCL investigators (2007) Effects of intense low density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38, 3198-3204.
9. Byington, R.P., Davis, B.R., Plehn, J.F., White, H.D., Baker, J., Cobbe, S.M. and Shepherd, J. (2001) Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 103, 387-392.
10. Kinlay, S., Schwartz, G.G., Olsson, A.G., Rifai, N., Sasiela, W.J., Szarek, M., Ganz, P. and Libby, P., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study investigators (2004) Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110, 386-391.
11. Song, Y.B., On, Y.K., Kim, J.H., Shin, D.H., Kim, J.S., Sung, J., Lee, S.H., Kim, W.S. and Lee, Y.T. (2008) The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am. Heart J. 156, e9-e16.
12. Maggioni, A.P., Fabbri, G., Lucci, D., Marchioli, R., Franzosi, M.G., Latini, R., Nicolosi, G.L., Porcu, M., Cosmi, F., Stefanelli, S. et al., GISSI-HF investigators (2009) Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur. Heart J. 30, 2327-2336.
13. Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, Jr, A.M., Kastelein, J.J., Koenig, W., Libby, P., Lorenzatti, A.J., MacFadyen, J.G. et al., JUPITER study group (2008) Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N. Engl. J. Med. 359, 2195-2207.
14. Moon, J.H., Kang, S.B., Park, J.S., Lee, B.W., Kang, E.S., Ahn, C.W., Lee, H.C. and Cha, B.S. (2011) Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor atorvastatin and hepatic LRP1 expression. Metabolism 60, 930-940.
15. Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A. et al., MEGA study group (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGAStudy): a prospective randomised controlled trial. Lancet 368, 1155-1163.
16. Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., Langendorfer, A., Stein, E.A., Kruyer, W. and Gotto, Jr, A.M. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622.
17. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H. and Packard, C.J., West of Scotland Coronary Prevention Study Group (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301-1307.
18. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357.
19. The Scandinavian Simvastatin Survival Study (4S) (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344, 1383-389.
20. Sever, P.S., Dahlöf, B., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S.E., Kristinsson, A., McInnes, G.T. et al., ASCOT investigators (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158.
21. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C. et al., Cholesterol and Recurrent Events Trial investigators (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001-1009.
22. Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., Joyal, S.V., Hill, K.A., Pfeffer, M.A. and Skene, A.M., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504.
23. LaRosa, J.C., Grundy, S.M., Waters, D.D., Shear, C., Barter, P., Fruchart, J.C., Gotto, A.M., Greten, H., Kastelein, J.J., Shepherd, J. et al., Treating to New Targets (TNT) investigators (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435.
24. Ray, K.K., Cannon, C.P., McCabe, C.H., Cairns, R., Tonkin, A.M., Sacks, F.M., Jackson, G. and Braunwald, E., PROVE IT-TIMI 22 investigators (2005) Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 46, 1405-1410.
25. Kinlay, S., Schwartz, G.G., Olsson, A.G., Rifai, N., Szarek, M., Waters, D.D., Libby, P. and Ganz, P., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study investigators (2008) Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler. Thromb. Vasc. Biol. 28, 142-147.
26. Kinlay, S., Schwartz, G.G., Olsson, A.G., Rifai, N., Leslie, S.J., Sasiela, W.J., Szarek, M., Libby, P. and Ganz, P. (2003) Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108, 1560-1566.
27. Di Sciascio, G., Patti, G., Pasceri, V., Gaspardone, A., Colonna, G. and Montinaro, A. (2009) Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J. Am. Coll. Cardiol. 54, 558-565.
28. Fichtlscherer, S., Schmidt-Lucke, C., Bojunga, S., Rössig, L., Heeschen, C., Dimmeler, S. and Zeiher, A.M. (2006) Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur. Heart J. 27, 1182-1190.
29. Ford, E.S., Giles, W.H. and Dietz, W.H. (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359.
30. Malik, S., Wong, N.D., Franklin, S.S., Kamath, T.V., L'Italien, G.J., Pio, J.R. and Williams, G.R. (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110, 1245-1250.
31. Halcox, J.P., Schenke, W.H., Zalos, G., Mincemoyer, R., Prasad, A., Waclawiw, M.A., Nour, K.R. and Quyyumi, A.A. (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106, 653-658.
32. Keaney, Jr, J.F., Larson, M.G., Vasan, R.S., Wilson, P.W., Lipinska, I., Corey, D., Massaro, J.M., Sutherland, P., Vita, J.A. and Benjamin, E.J., Framingham Study (2003) Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler. Thromb. Vasc. Biol. 23, 434-439.
33. D'Agnillo, F., Wood, F., Porras, C., Macdonald, V.W. and Alayash, A.I. (2000) Effects of hypoxia and glutathione depletion on hemoglobin-and myoglobin-mediated oxidative stress toward endothelium. Biochim. Biophys. Acta 1495, 150-159.
34. Berliner, J.A., Territo, M.C., Sevanian, A., Ramin, S., Kim, J.A., Bamshad, B., Esterson, M. and Fogelman, A.M. (1990) Minimally modified LDL stimulates monocyte endothelial interaction. J. Clin. Invest. 85, 1260-1266.
35. Aoki, M., Nata, T., Morishita, R., Matsushita, H., Nakagami, H., Yamamoto, K., Yamazaki, K., Nakabayashi, M., Ogihara, T. and Kaneda, Y. (2001) Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension 38, 48-55.
36. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G. and Isner, J.M. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967.
37. Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A., Böhm, M. and Nickenig, G. (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353, 999-1007.
38. Shi, Q., Rafii, S., Wu, M.H., Wijelath, E.S., Yu, C., Ishida, A., Fujita, Y., Kothari, S., Mohle, R., Sauvage, L.R. et al. (1998) Evidence for circulating bone marrow-derived endothelial cells. Blood 92, 362-367.
39. Walter, D.H., Rittig, K., Bahlmann, F.H., Kirchmair, R., Silver, M., Murayama, T., Nishimura, H., Losordo, D.W., Asahara, T. and Isner, J.M. (2002) Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105, 3017-3024.
40. Rafii, S. and Lyden, D. (2003) Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9, 702-712.
41. Blackburn, E.H. (2001) Switching and signaling at the telomere. Cell 106, 661-673.
42. Satoh, M., Ishikawa, Y., Takahashi, Y., Itoh, T., Minami, Y. and Nakamura, M. (2008) Association between oxidative DNA damage and telomere shortening in circulating endothelial progenitor cells obtained from metabolic syndrome patients with coronary artery disease. Atherosclerosis 198, 347-353.
43. Spyridopoulos, I., Haendeler, J., Urbich, C., Brummendorf, T.H., Oh, H., Schneider, M.D., Zeiher, A.M. and Dimmeler, S. (2004) Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 110, 3136-3142.
44. Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., Brown, B.G., Ganz, P., Vogel, R.A., Crowe, T., Howard, G., Cooper, C.J., Brodie, B. et al., REVERSAL investigators (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080.
45. Satoh, M., Minami, Y., Takahashi, Y., Tabuchi, T., Itoh, T. and Nakamura, M. (2009) Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease. Clin. Sci. 116, 827-835.
46. Takeda, K., Kaisho, T. and Akira, S. (2003) Toll-like receptors. Annu. Rev. Immunol. 21, 335-376.
47. Medzhitov, R. (2001) Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145.
48. Akira, S., Takeda, K. and Kaisho, T. (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2, 675-680.
49. Medzhitov, R., Preston-Hurlburt, P. and Janeway, Jr, C.A. (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397.
50. Modlin, R.L., Brightbill, H.D. and Godowski, P. (1999) The Toll of innate immunity on microbial pathogens. N. Engl. J. Med. 340, 1834-1835.
51. Satoh, M., Shimoda, Y., Maesawa, C., Akatsu, T., Ishikawa, Y., Minami, Y., Itoh, T. and Nakamura, M. (2006) Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int. J. Cardiol. 109, 226-234.
52. Satoh, M., Shimoda, Y., Akatsu, T., Ishikawa, Y., Minami, Y. and Nakamura, M. (2006) Elevated circulating levels of heat shock protein 70 are related to systemic inflammatory reaction through monocyte Toll signal in patients with heart failure after acute myocardial infarction. Eur. J. Heart Fail. 8, 810-815.
53. Ishikawa, Y., Satoh, M., Itoh, T., Minami, Y., Takahashi, Y. and Akamura, M. (2008) Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction. Clin. Sci. 115, 133-140.
54. Michelsen, K.S., Wong, M.H., Shah, P.K., Zhang, W., Yano, J., Doherty, T.M., Akira, S., Rajavashisth, T.B. and Arditi, M. (2004) Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U.S.A. 101, 10679-10684.
55. Nissen, S. E., Tuzcu, E.M., Schoenhagen, P., Crowe, T., Sasiela, W.J., Tsai, J., Orazem, J., Magorien, R.D., O'Shaughnessy, C. and Ganz, P., Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) investigators (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352, 29-38.
56. Ridker, P.M., Cannon, C.P., Morrow, D., Rifai, N., Rose, L.M., McCabe, C.H., Pfeffer, M.A. and Braunwald, E., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) investigators (2005) C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28.
57. Yilmaz, A., Reiss, C., Weng, A., Cicha, I., Stumpf, C., Steinkasserer, A., Daniel, W.G. and Garlichs, C.D. (2006) Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J. Leukoc. Biol. 79, 529-538.
58. Moutzouri, E., Tellis, C.C., Rousouli, K., Liberopoulos, E.N., Milionis, H.J., Elisaf, M.S. and Tselepis, A.D. (2012) Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide-induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis 225, 381-387.
59. Lusis, A.J. (2000) Atherosclerosis. Nature 407, 233-241.
60. Brandes, R.P., Fleming, I. and Busse, R. (2005) Endothelial aging. Cardiovasc. Res. 66, 286-294.
61. Kudo, F.A., Warycha, B., Juran, P.J., Asada, H., Teso, D., Aziz, F., Frattini, J., Sumpio, B.E., Nishibe, T., Cha, C. et al. (2005) Differential responsiveness of early-and late-passage endothelial cells to shear stress. Am. J. Surg. 190, 763-769.
62. Minamino, T. and Komuro, I. (2007) Vascular cell senescence: contribution to atherosclerosis. Circ. Res. 100, 15-26.
63. Frye, R.A. (2000) Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273, 793-798.
64. Braunstein, M., Rose, A.B., Holmes, S.G., Allis, C.D. and Broach, J.R. (1993) Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. Genes Dev. 7, 592-604.
65. Potente, M. and Dimmeler, S. (2008) Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 7, 2117-2122.
66. Ota, H., Akishita, M., Eto, M., Iijima, K., Kaneki, M. and Ouchi, Y. (2007) Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J. Mol. Cell. Cardiol. 43, 571-579.
67. Ota, H., Eto, M., Kano, M.R., Kahyo, T., Setou, M., Ogawa, S., Iijima, K., Akishita, M. and Ouchi, Y. (2010) Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler. Thromb. Vasc. Biol. 30, 2205-2211.
68. Csiszar, A., Labinskyy, N., Jimenez, R., Pinto, J.T., Ballabh, P., Losonczy, G., Pearson, K.J., de Cabo, R. and Ungvari, Z. (2009) Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1. Mech. Ageing Dev. 130, 518-527.
69. Yang, J., Wang, N., Zhu, Y. and Feng, P. (2011) Roles of SIRT1 in high glucose-induced endothelial impairment: association with diabetic atherosclerosis. Arch. Med. Res. 42, 354-360.
70. Tabuchi, T., Satoh, M., Itoh, T. and Nakamura, M. (2012) MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin. Sci. 123, 161-171.
71. Satoh, M., Ishikawa, Y., Minami, Y., Takahashi, Y. and Nakamura, M. (2008) Role of Toll like receptor signaling pathway in ischemic coronary artery disease. Front. Biosci. 13, 6708-6715.
72. Kawamura, A., Baitsch, D., Telgmann, R., Feuerborn, R., Weissen-Plenz, G., Hagedorn, C., Saku, K., Brand-Herrmann, S.M., von Eckardstein, A., Assmann, G. et al. (2007) Apolipoprotein E interrupts interleukin-1beta signaling in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 27, 1610-1617.
73. Yearley, J.H., Xia, D., Pearson, C.B., Carville, A., Shannon, R.P. and Mansfield, K.G. (2009) Interleukin-18 predicts atherosclerosis progression in SIV-infected and uninfected rhesus monkeys (Macaca mulatta) on a high-fat/high-cholesterol diet. Lab. Invest. 89, 657-667.
74. Galea, J., Armstrong, J., Gadsdon, P., Holden, H., Francis, S.E. and Holt, C.M. (1996) Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 16, 1000-1006.
75. Blankenberg, S., Tiret, L., Bickel, C., Peetz, D., Cambien, F., Meyer, J. and Rupprecht, H.J., AtheroGene investigators (2002) Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106, 24-30.
76. Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M., Moriwaki, H. and Seishima, M. (2003) Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 656-660.
77. Elhage, R., Jawien, J., Rudling, M., Ljunggren, H.G., Takeda, K., Akira, S., Bayard, F. and Hansson, G.K. (2003) Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 59, 234-240.
78. Leemans, J.C., Cassel, S.L. and Sutterwala, F.S. (2011) Sensing damage by the NLRP3 inflammasome. Immunol. Rev. 243, 152-162.
79. Schroder, K., Zhou, R. and Tschopp, J. (2010) The NLRP3 inflammasome: a sensor for metabolic danger? Science 327, 296-300.
80. Tschopp, J. and Schroder, K. (2010) NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat. Rev. Immunol. 10, 210-215.
81. Schroder, K. and Tschopp, J. (2010) The inflammasones. Cell 140, 821-832.
82. Rajamäki, K., Lappalainen, J., Oörni, K., Välimäki, E., Matikainen, S., Kovanen, P.T. and Eklund, K.K. (2010) Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 5, e11765.
83. Satoh, M., Tabuchi, T., Itoh, T. and Nakamura, M. (2014) NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin. Clin. Sci. 126, 233-241.
84. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-97.
85. Kim, V.N. (2005) Small RNAs: classification, biogenesis, and function. Mol. Cells 19, 1-15.
86. Felli, N., Fontana, L., Pelosi, E., Botta, R., Bonci, D., Facchiano, F., Liuzzi, F., Lulli, V., Morsilli, O., Santoro, S. et al. (2005) MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl. Acad. Sci. U.S.A. 102, 18081-18086.
87. Tuccoli, A., Poliseno, L. and Rainaldi, G. (2006) miRNAs regulate miRNAs: coordinated transcriptional and post-transcriptional regulation. Cell Cycle 5, 2473-2476.
88. Suarez, Y., Fernandez-Hernando, C., Pober, J.S. and Sessa, W.C. (2007) Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ. Res. 100, 1164-1173.
89. Poliseno, L., Tuccoli, A., Mariani, L., Evangelista, M., Citti, L., Woods, K., Mercatanti, A., Hammond, S. and Rainaldi, G. (2006) MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108, 3068-3071.
90. Lewis, B.P., Burge, C.B. and Bartel, DP. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20.
91. Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M. et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U.S.A. 101, 2999-3004.
92. Altuvia, Y., Landgraf, P., Lithwick, G., Elefant, N., Pfeffer, S., Aravin, A., Brownstein, M.J., Tuschl, T. and Margalit, H. (2005) Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 33, 2697-2706.
93. Minami, Y., Satoh, M., Maesawa, C., Takahashi, Y., Tabuchi, T., Itoh, T. and Nakamura, M. (2009) Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur. J. Clin. Invest. 39, 359-367.
94. Chen, X.M., Splinter, P.L., O'Hara, S.P. and LaRusso, N.F. (2007) A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J. Biol. Chem. 282, 28929-28938.
95. O'Hara, S.P., Splinter, P.L., Gajdos, G.B., Trussoni, C.E., Fernandez-Zapico, M.E., Chen, X.M. and LaRusso, N.F. (2010) NFkappaB p50-CCAAT/enhancer-binding protein beta (C/EBPbeta)-mediated transcriptional repression of microRNA let-7i following microbial infection. J. Biol. Chem. 285, 216-225.
96. Satoh, M., Tabuchi, T., Minami, Y., Takahashi, Y., Itoh, T. and Nakamura, M. (2012) Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal. Immunobiology 217, 533-539.
97. Mason, R.P., Walter, M.F., Day, C.A. and Jacob, R.F. (2006) Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J. Biol. Chem. 281, 9337-9345.
98. Wassmann, S., Laufs, U., Muller, K., Konkol, C., Ahlbory, K., Baumer, A.T., Bäumer, A.T., Linz, W., Böhm, M. and Nickenig, G. (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 22, 300-305.
99. Yamakuchi, M., Ferlito, M. and Lowenstein, CJ. (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U.S.A. 105, 13421-13426.
100. Yamakuchi, M. and Lowenstein, C.J. (2009) MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8, 712-715.